Vimarsana
Biggest News Aggregation in the World

Amaurosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amaurosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amaurosis Today - Breaking & Trending Today

Siblings with rare eye disorder ready for experimental UK treatment: A Christmas miracle - Vimarsana News

Siblings with rare eye disorder ready for experimental UK treatment: A Christmas miracle

One familys' Christmas wishes came true after their two sons who suffer from a rare inherited eye disorder were given the green light to receive an experimental

Source: fox56.com
Toddler suffering from 'one-in-a-million' Leber congenital amaurosis takes medical leap of faith - Vimarsana News

Toddler suffering from 'one-in-a-million' Leber congenital amaurosis takes medical leap of faith

A rare opportunity has arisen for Ciro Carrascull - but it's halfway across the world.

VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both Leber Congenital Amaurosis and Cone-Rod dystrophy - Vimarsana News

VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both Leber Congenital Amaurosis and Cone-Rod dystrophy

Variant, a company dedicated to developing innovative treatments for inherited eye orphan diseases, announces the decision of the European Commission to grant Orphan Drug Designation (ODD) for VAR002

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis - Vimarsana News

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA). The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. "We believe the grant...